PA-BOOMI
6.8.2024 15:01:34 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced the release of a new report, “A Playbook for Crafting AI Strategy,” produced in collaboration with MIT Technology Review Insights. This comprehensive study — which includes a global survey of C-suite and senior data executives, including in-depth interviews conducted with business leaders on data and AI — sheds light on the current state of enterprise AI adoption, and offers actionable strategies for navigating the transformative landscape of artificial intelligence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240806027370/en/
Boomi Releases Strategic Playbook for Effective AI Adoption (Graphic: Business Wire)
As businesses grapple with ambitious AI predictions — such as PwC's forecast that AI could contribute an astounding $15.7 trillion to global GDP by 20301 — major hurdles remain in the journey from pilot projects to enterprise-wide deployment. As an example, just 5.4% of US businesses utilized AI to produce a product or service in 2024,2 signifying a pressing need for strategic and organizational shifts to leverage AI effectively.
Key findings from the report highlight the following trends and challenges:
- AI ambitions are substantial, but few have scaled beyond pilots. Fully 95% of companies surveyed are already using AI and 99% expect to in the future. But few organizations have graduated beyond pilot projects: 76% have deployed AI in just one to three use cases. As half of companies expect to fully deploy AI across all business functions within two years, this year is key to establishing foundations for enterprise-wide AI.
- AI-readiness spending is slated to rise significantly. Overall, AI spending in 2022 and 2023 was modest or flat for most companies, with only one in four increasing their spending by more than a quarter. That is set to change in 2024, with nine in ten respondents expecting to increase AI spending on data readiness (including platform modernization, cloud migration, and data quality) and in adjacent areas like strategy, cultural change, and business models. Four in ten expect to increase spending by 10 to 24%, and one-third expect to increase spending by 25 to 49%.
- Data liquidity is one of the most important attributes for AI deployment. The ability to seamlessly access, combine, and analyze data from various sources enables firms to extract relevant information and apply it effectively to specific business scenarios. It also eliminates the need to sift through vast data repositories, as the data is already curated and tailored to the task at hand.
- Data quality is a major limitation for AI deployment. Half of respondents cite data quality as the most limiting data issue in deployment. This is especially true for larger firms with more data and substantial investments in legacy IT infrastructure. Companies with revenues of over $10 billion are the most likely to cite both data quality and data infrastructure as limiters, suggesting that organizations presiding over larger data repositories find the problem substantially harder.
- Companies are not rushing into AI. Nearly all organizations (98%) say they are willing to forgo being the first to use AI if that ensures they can deliver it safely and securely. Governance, security, and privacy are the biggest brake on the speed of AI deployment, cited by 45% of respondents (and a full 65% of respondents from the largest companies).
“Over the last year, organizations have come to understand the power and potential of AI,” said Matt McLarty, CTO at Boomi. “This year, those organizations are seeking to shift from small pilots to enterprise-wide deployment of AI at scale.”
“A Playbook for Crafting AI Strategy” can assist with the next steps of an AI journey, offering the following principles as guidance:
- This is a critical year for building AI foundations. As organizations strive to meet ambitious short-term AI goals, they are discovering that having the right data foundation is critical. Organizations are doubling down on investments in data quality, data liquidity, and IT infrastructure.
- The highest-leverage AI use cases drive targeted, business-specific results. Although general-purpose generative AI use cases are increasingly simple to implement, they are equally available to competitors and customers. The most valuable use cases are those that create unique competitive advantages for the business.
- Financial considerations and partnerships are key. This year, the costs of AI — from GPUs to skilled talent to energy consumption — must be accounted for, and a realistic approach to measuring AI’s ROI must be developed. Because few organizations will go it alone when it comes to AI, making decisions about the right partners, vendors, and tools will be essential to most companies’ AI futures.
- Speed of AI adoption is being moderated by a realistic assessment of its risks. Organizations are rightly cautious about the risks posed by injudicious use of AI, and essentially all agree that caution is preferable to first-mover advantage when scaling AI. An emerging regulatory environment and a better understanding of how the risks of AI can be mitigated should serve to speed adoption.
“The biggest factor holding back AI implementation is not knowing where to start,” said Matt McLarty, CTO at Boomi. “You don’t actually have to be an expert on how to create generative AI in order to get value from generative AI. As organizations seek to harness AI's transformative potential, our report serves as a crucial playbook, guiding business leaders through the complexities of AI strategy formulation.”
Download the complete report, “A Playbook for Crafting AI Strategy.”
Additional Resources
- Learn more about the Boomi Enterprise Platform
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi, the intelligent integration and automation leader, helps organizations around the world automate and streamline critical processes to achieve business outcomes faster. Harnessing advanced AI capabilities, the Boomi Enterprise Platform seamlessly connects systems and manages data flows with API management, integration, data management, and AI orchestration in one comprehensive solution. With a customer base exceeding 20,000 companies globally and a rapidly expanding network of 800+ partners, Boomi is revolutionizing the way enterprises of all sizes achieve business agility and operational excellence. Discover more at boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
__________________________
1 Sizing the prize: What’s the real value of AI for your business and how can you capitalise?” PwC, 2017, https://preview.thenewsmarket.com/Previews/PWC/DocumentAssets/476830.pdf.
2 Richard Vanderford, “Generative AI Isn’t Ubiquitous in the Business World—at Least Not Yet,” The Wall Street Journal, April 7, 2024, https://www.wsj.com/articles/generative-ai-isnt-ubiquitous-in-the-business-worldat-least-not-yet-07c07f01?mod=tech_lead_pos3.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806027370/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
